The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Pharmaceutical companies, as highlighted in ISR's 2023 report, currently delegate an average of 52% of their commercial manufacturing and 51% of their clinical trial manufacturing projects for oral solid dose products to external CDMOs. The seamless technology transfer required to shift projects to a CDMO must be reliable and robust to avoid delays due to unforeseen challenges or communication breakdowns. Selecting an unsuitable CDMO can lead to costly repercussions such as postponed product launches and delayed delivery to patients in need.
Our article, "5 CDMO attributes for reliable technology transfers", explores strategies for ensuring reliable and simple technology transfers and the importance of collaborating with a CDMO that embodies five key attributes. These include flexible capacity at scale, proven industry expertise, and the utilization of advanced digital technologies, among others.
